X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Unichem Lab - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs UNICHEM LAB - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH UNICHEM LAB PANACEA BIOTECH/
UNICHEM LAB
 
P/E (TTM) x 175.0 29.2 598.4% View Chart
P/BV x 3.9 3.1 126.2% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PANACEA BIOTECH   UNICHEM LAB
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
UNICHEM LAB
Mar-16
PANACEA BIOTECH/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs149334 44.5%   
Low Rs82174 47.3%   
Sales per share (Unadj.) Rs84.1146.9 57.3%  
Earnings per share (Unadj.) Rs-18.311.9 -153.9%  
Cash flow per share (Unadj.) Rs-6.716.2 -41.4%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs83.7105.1 79.6%  
Shares outstanding (eoy) m61.2590.84 67.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.41.7 79.4%   
Avg P/E ratio x-6.321.4 -29.5%  
P/CF ratio (eoy) x-17.215.7 -109.9%  
Price / Book Value ratio x1.42.4 57.1%  
Dividend payout %016.8 0.0%   
Avg Mkt Cap Rs m7,07423,073 30.7%   
No. of employees `0002.85.7 48.5%   
Total wages/salary Rs m1,4492,558 56.7%   
Avg. sales/employee Rs Th1,874.12,352.5 79.7%   
Avg. wages/employee Rs Th527.0450.9 116.9%   
Avg. net profit/employee Rs Th-407.7190.4 -214.1%   
INCOME DATA
Net Sales Rs m5,15413,346 38.6%  
Other income Rs m100192 52.0%   
Total revenues Rs m5,25413,538 38.8%   
Gross profit Rs m-7661,639 -46.8%  
Depreciation Rs m711390 182.3%   
Interest Rs m1,50329 5,218.8%   
Profit before tax Rs m-2,8811,412 -204.0%   
Minority Interest Rs m110-   
Prior Period Items Rs m-6-4 154.1%   
Extraordinary Inc (Exp) Rs m1,771-35 -5,016.7%   
Tax Rs m17293 5.7%   
Profit after tax Rs m-1,1211,080 -103.8%  
Gross profit margin %-14.912.3 -121.1%  
Effective tax rate %-0.620.7 -2.8%   
Net profit margin %-21.88.1 -268.8%  
BALANCE SHEET DATA
Current assets Rs m3,8105,979 63.7%   
Current liabilities Rs m8,3652,432 344.0%   
Net working cap to sales %-88.426.6 -332.5%  
Current ratio x0.52.5 18.5%  
Inventory Days Days15663 246.9%  
Debtors Days Days6760 111.4%  
Net fixed assets Rs m14,4806,403 226.2%   
Share capital Rs m61182 33.7%   
"Free" reserves Rs m9039,293 9.7%   
Net worth Rs m5,1279,548 53.7%   
Long term debt Rs m5,832230 2,531.1%   
Total assets Rs m19,43312,843 151.3%  
Interest coverage x-0.950.0 -1.8%   
Debt to equity ratio x1.10 4,713.7%  
Sales to assets ratio x0.31.0 25.5%   
Return on assets %2.08.6 22.7%  
Return on equity %-21.911.3 -193.3%  
Return on capital %3.614.3 25.4%  
Exports to sales %24.529.2 83.9%   
Imports to sales %10.26.3 160.5%   
Exports (fob) Rs m1,2643,900 32.4%   
Imports (cif) Rs m525847 62.0%   
Fx inflow Rs m1,5394,356 35.3%   
Fx outflow Rs m9421,162 81.0%   
Net fx Rs m5973,194 18.7%   
CASH FLOW
From Operations Rs m5991,119 53.5%  
From Investments Rs m-438-853 51.3%  
From Financial Activity Rs m-303-334 90.5%  
Net Cashflow Rs m-141-68 206.9%  

Share Holding

Indian Promoters % 74.5 50.1 148.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 15.1 4.0%  
FIIs % 1.3 3.0 43.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 31.7 74.4%  
Shareholders   10,259 20,176 50.8%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  FDC LTD.  ASTRAZENECA PHARMA  BIOCON LTD  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; IT Stocks Witness Buying Interest(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the IT sector and FMCG sector witnessing maximum buying interest.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 21, 2018 12:49 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS